Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B is a monthly open access English journal published by Elsevier on behalf of the Institute of Materia Medica of the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, founded in 2011, covering all areas of pharmaceutical sciences, with a 2025 Journal Impact Factor of 14.6（Acta Pharmaceutica Sinica B）（APSB）是（Elsevier）代表中国医学科学院药物研究所与中国药学会出版的月刊开放获取英文期刊，2011 年创刊，涵盖药学各领域，2025 年影响因子为 14.6。
Scope
- It publishes significant original research articles, rapid communications and high quality reviews across pharmaceutical sciences该刊发表药学各领域的重要原创研究论文、快报与高质量综述。
- Its coverage includes pharmacology and pharmaceutics其报道范围涵盖药理学与药剂学。[1]
- It covers medicinal chemistry and natural products该刊涵盖药物化学与天然产物。[2]
- It covers pharmacognosy and pharmaceutical analysis该刊涵盖生药学与药物分析。
- It covers pharmacokinetics and drug discovery该刊涵盖药代动力学与药物发现。[3]
- It encourages submissions from all areas of pharmaceutical sciences worldwide该刊鼓励全球学者投递药学各领域的稿件。
History
- It was founded in June 2011 as the English series journal of Acta Pharmaceutica Sinica该刊于 2011 年 6 月创刊，是《药学学报》的英文系列刊。
- It is published by Elsevier on ScienceDirect in an open access model该刊由（Elsevier）在（ScienceDirect）平台上以开放获取模式出版。
- It began as a bimonthly journal and changed to monthly in 2020该刊起初为双月刊，2020 年改为月刊。
- It was included by Chemical Abstracts in 2011, PubMed Central in 2015 and the Science Citation Index in 2017该刊 2011 年被（Chemical Abstracts）收录，2015 年被（PubMed Central）收录，2017 年被（Science Citation Index）收录。
- Its article publishing charge is USD 2,600 and articles use a CC BY-NC-ND license其文章处理费为 2600 美元，文章采用（CC BY-NC-ND）许可。
- Its impact factor was 11.413 in 2021 and 14.6 in 2025其影响因子 2021 年为 11.413，2025 年为 14.6。
Editors
- Its Editor-in-Chief is Jiandong Jiang, an academician of the Chinese Academy of Engineering其主编为蒋建东，他是中国工程院院士。
- Jiandong Jiang has served since 2011 and directs the Institute of Materia Medica蒋建东自 2011 年起任主编，并任药物研究所所长。
- Its Co-Editor-in-Chief is Rui Wang, appointed in June 2022其共同主编为王锐，于 2022 年 6 月受聘。
- Rui Wang is also an academician of the Chinese Academy of Engineering王锐亦为中国工程院院士。
- The journal is sponsored by the Chinese Pharmaceutical Association and the Institute of Materia Medica该刊由中国药学会与中国医学科学院药物研究所共同主办。
- It is produced and hosted by Elsevier on ScienceDirect该刊由（Elsevier）制作并托管于（ScienceDirect）平台。
References
- ^Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 2020, 10: 766-788. DOI: 10.1016/j.apsb.2020.02.008
- ^Masoud G N, Li W. HIF-1 pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B, 2015, 5: 378-389. DOI: 10.1016/j.apsb.2015.05.007
- ^Sun D, Gao W, Hu H, et al. Why 90 percent of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, 2022, 12: 3049-3062. DOI: 10.1016/j.apsb.2022.02.002